<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="ee" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">ee</book-part-id>
      <title-group>
        <title>Ethylmalonic Encephalopathy</title>
        <alt-title alt-title-type="alt-title">Synonym: ETHE1 Deficiency</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Di Meo</surname>
            <given-names>Ivano</given-names>
          </name>
          <degrees>PhD</degrees>
          <xref ref-type="aff" rid="ee.Tc.aff1"/>
          <email>ivano.dimeo@istituto-besta.it</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Lamperti</surname>
            <given-names>Costanza</given-names>
          </name>
          <degrees>MD</degrees>
          <xref ref-type="aff" rid="ee.Tc.aff1"/>
          <email>costanza.lamperti@istituto-besta.it</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Tiranti</surname>
            <given-names>Valeria</given-names>
          </name>
          <degrees>PhD</degrees>
          <xref ref-type="aff" rid="ee.Tc.aff1"/>
          <email>valeria.tiranti@istituto-besta.it</email>
        </contrib>
      </contrib-group>
      <aff id="ee.Tc.aff1">Division of Molecular Neurogenetics<break/>IRCCS Foundation Carlo Besta Neurological Institute<break/>Milano, Italy</aff>
      <pub-history>
        <date date-type="created">
          <day>21</day>
          <month>9</month>
          <year>2017</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="tef-ov" document-type="chapter">Esophageal Atresia/Tracheoesophageal Fistula Overview</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="fbln5-cutis-laxa" document-type="chapter">
<italic toggle="yes">FBLN5</italic>-Related Cutis Laxa</related-object>
      <abstract id="ee.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>Ethylmalonic encephalopathy (EE) is a severe, early-onset, progressive disorder characterized by developmental delay / mild-to-severe intellectual disability; generalized infantile hypotonia that evolves into hypertonia, spasticity, and (in some instances) dystonia; generalized tonic-clonic seizures; and generalized microvascular damage (diffuse and spontaneous relapsing petechial purpura, hemorrhagic suffusions of mucosal surfaces, and chronic hemorrhagic diarrhea). Infants sometimes have frequent vomiting and loss of social interaction. Speech is delayed and in some instances absent. Swallowing difficulties and failure to thrive are common. Children may be unable to walk without support and may be wheelchair bound. Neurologic deterioration accelerates following intercurrent infectious illness, and the majority of children die in the first decade.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>The diagnosis of EE is suggested by clinical findings and the laboratory findings of increased blood lactate levels, C4- and C5-acylcarnitine esters, plasma thiosulphate, and urinary ethylmalonic acid.</p>
          <p>The diagnosis is established by identification of biallelic pathogenic variants in <italic toggle="yes">ETHE1</italic> on molecular genetic testing.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> Multi-specialty care that includes child neurology, pediatrics, clinical genetics, nutrition, gastroenterology, pain management, and physical therapy can help with timely detection and treatment of the multi-organ dysfunction that characterizes EE. Treatment is primarily supportive including antispastic medications, muscle relaxants, and antiepileptic drugs (AEDs). Physical therapy early in the disease course can help prevent contractures. For severe diarrhea, it is important to maintain hydration and caloric intake. Tube feeding is often necessary.</p>
          <p><italic toggle="yes">Prevention of secondary complications:</italic> Prevention of infections that could be fatal.</p>
          <p><italic toggle="yes">Surveillance:</italic> Recommendations based on individual patient findings can include: monitoring of feeding and electrolyte status particularly in those with severe diarrhea; monitoring of seizures and response to AEDs.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>EE is inherited in an autosomal recessive manner. At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. No individuals diagnosed with EE have been known to reproduce. Once the <italic toggle="yes">ETHE1</italic> pathogenic variants have been identified in an affected family member, carrier testing for at-risk relatives, prenatal testing for a pregnancy at increased risk, and preimplantation genetic diagnosis are possible.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="ee.Diagnosis">
        <title>Diagnosis</title>
        <sec id="ee.Suggestive_Findings">
          <title>Suggestive Findings</title>
          <p>Ethylmalonic encephalopathy (EE) <bold>should be suspected</bold> in an individual with the following clinical findings, preliminary laboratory findings, and brain MRI findings [<xref ref-type="bibr" rid="ee.REF.dionisivici.2016.1045">Dionisi-Vici et al 2016</xref>].</p>
          <p>
            <bold>Clinical findings</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Global neurologic impairment</p>
              <list list-type="bullet">
                <list-item>
                  <p>Early-onset progressive psychomotor regression</p>
                </list-item>
                <list-item>
                  <p>Seizures</p>
                </list-item>
                <list-item>
                  <p>Dystonia</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>Diffuse microvasculature injury</p>
              <list list-type="bullet">
                <list-item>
                  <p>Petechiae and/or purpura</p>
                </list-item>
                <list-item>
                  <p>Orthostatic acrocyanosis</p>
                </list-item>
                <list-item>
                  <p>Hemorrhagic suffusions of mucosal surfaces</p>
                </list-item>
                <list-item>
                  <p>Chronic hemorrhagic diarrhea</p>
                </list-item>
              </list>
            </list-item>
          </list>
          <p>
            <bold>Preliminary laboratory findings</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Increased blood lactate levels (normal range: 6-22 mg/dL)</p>
            </list-item>
            <list-item>
              <p>Increased blood C4-acylcarnitine esters (normal range: &#x0003c;0.9 &#x003bc;mol/L) [<xref ref-type="bibr" rid="ee.REF.merinero.2006.685">Merinero et al 2006</xref>, <xref ref-type="bibr" rid="ee.REF.zafeiriou.2007.78">Zafeiriou et al 2007</xref>]&#x000a0;*</p>
            </list-item>
            <list-item>
              <p>Increased blood C5-acylcarnitine esters (normal range: &#x0003c;0.3 &#x003bc;mol/L) [<xref ref-type="bibr" rid="ee.REF.merinero.2006.685">Merinero et al 2006</xref>, <xref ref-type="bibr" rid="ee.REF.zafeiriou.2007.78">Zafeiriou et al 2007</xref>]&#x000a0;*</p>
            </list-item>
            <list-item>
              <p>Increased plasma thiosulphate (normal range: &#x0003c;4 &#x003bc;mol/L)</p>
            </list-item>
            <list-item>
              <p>Increased urinary ethylmalonic acid (normal range: &#x0003c;10 &#x003bc;mol/mmol creatinine) evaluated on spot urine [<xref ref-type="bibr" rid="ee.REF.merinero.2006.685">Merinero et al 2006</xref>, <xref ref-type="bibr" rid="ee.REF.zafeiriou.2007.78">Zafeiriou et al 2007</xref>]</p>
            </list-item>
          </list>
          <p>*&#x000a0;More data are needed to define the range of C4/C5 acylcarnitine elevation in individuals with molecularly proven EE.</p>
          <p><bold>Newborn screening (NBS).</bold> Tandem mass spectroscopy can identify C4 elevation in a NBS dried blood spot; however, NBS for EE is not available in the US as there is no definitive treatment (see <xref ref-type="sec" rid="ee.Therapies_Under_Investigation">Therapies Under Investigation</xref>). Note: (1) NBS may be performed elsewhere in the world. (2) C4 elevation can also be found in <related-object link-type="booklink" source-id="gene" document-id="scad" document-type="chapter">primary short-chain acyl-CoA dehydrogenase (SCAD) deficiency</related-object> [<xref ref-type="bibr" rid="ee.REF.mchugh.2011.230">McHugh et al 2011</xref>]; an <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.acmg.net/StaticContent/ACT/Algorithms/Visio-C4.pdf">algorithm</ext-link> (pdf) from the American College of Medical Genetics can be used to distinguish the two disorders.</p>
          <p>
            <bold>Brain MRI</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Symmetric patchy T<sub>2</sub>-weighted signals in the basal ganglia, periventricular white matter and dentate nuclei, brain stem, and cerebellar white matter. In some instances, cortical atrophy and diffuse leukoencephalopathy are present.</p>
            </list-item>
            <list-item>
              <p>Atypical neuroradiologic patterns were also reported [<xref ref-type="bibr" rid="ee.REF.grosso.2002.1446">Grosso et al 2002</xref>, <xref ref-type="bibr" rid="ee.REF.heberle.2006.329">Heberle et al 2006</xref>].</p>
            </list-item>
          </list>
        </sec>
        <sec id="ee.Establishing_the_Diagnosis">
          <title>Establishing the Diagnosis</title>
          <p>The diagnosis of ethylmalonic encephalopathy <bold>is established</bold> in a proband with suggestive clinical and laboratory findings and identification of biallelic pathogenic variants in <italic toggle="yes">ETHE1</italic> on molecular genetic testing (see <xref ref-type="table" rid="ee.T.molecular_genetic_testing_used_in_e">Table 1</xref>).</p>
          <p><bold>Single-gene testing</bold> is the molecular genetic testing approach indicated. Sequence analysis of <italic toggle="yes">ETHE1</italic> is performed first and followed by gene-targeted deletion/duplication analysis if only one or no pathogenic variant is found.</p>
          <table-wrap id="ee.T.molecular_genetic_testing_used_in_e" orientation="portrait" position="anchor">
            <label>Table 1. </label>
            <caption>
              <p>Molecular Genetic Testing Used in Ethylmalonic Encephalopathy</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_ee.T.molecular_genetic_testing_used_in_e_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene&#x000a0;<sup>1</sup></th>
                  <th id="hd_h_ee.T.molecular_genetic_testing_used_in_e_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Test Method</th>
                  <th id="hd_h_ee.T.molecular_genetic_testing_used_in_e_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Proportion of Pathogenic Variants&#x000a0;<sup>2</sup> in Probands Detectable by This Method</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_ee.T.molecular_genetic_testing_used_in_e_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                    <italic toggle="yes">ETHE1</italic>
                  </td>
                  <td headers="hd_h_ee.T.molecular_genetic_testing_used_in_e_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>3</sup></td>
                  <td headers="hd_h_ee.T.molecular_genetic_testing_used_in_e_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">67/86&#x000a0;<sup>4</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_ee.T.molecular_genetic_testing_used_in_e_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Gene-targeted deletion/duplication analysis&#x000a0;<sup>5</sup></td>
                  <td headers="hd_h_ee.T.molecular_genetic_testing_used_in_e_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">19/86&#x000a0;<sup>4,&#x000a0;6</sup></td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="ee.TF.1.1">
                <label>1. </label>
                <p>See <related-object source-id="gene" document-id="ee" object-id="ee.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein.</p>
              </fn>
              <fn id="ee.TF.1.2">
                <label>2. </label>
                <p>See <xref ref-type="sec" rid="ee.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants detected in this gene.</p>
              </fn>
              <fn id="ee.TF.1.3">
                <label>3. </label>
                <p>Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
              </fn>
              <fn id="ee.TF.1.4">
                <label>4. </label>
                <p><xref ref-type="bibr" rid="ee.REF.tiranti.2006.340">Tiranti et al [2006]</xref>, <xref ref-type="bibr" rid="ee.REF.mineri.2008.473">Mineri et al [2008]</xref></p>
              </fn>
              <fn id="ee.TF.1.5">
                <label>5. </label>
                <p>Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods that may be used include: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications.</p>
              </fn>
              <fn id="ee.TF.1.6">
                <label>6. </label>
                <p>Deletion of exon 4 and deletion of exons 1 to 7 have been detected frequently [<xref ref-type="bibr" rid="ee.REF.tiranti.2006.340">Tiranti et al 2006</xref>, <xref ref-type="bibr" rid="ee.REF.mineri.2008.473">Mineri et al 2008</xref>].</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
        </sec>
      </sec>
      <sec id="ee.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="ee.Clinical_Description">
          <title>Clinical Description</title>
          <p>Ethylmalonic encephalopathy (EE) is a severe, early-onset, progressive disorder, typically characterized by the following major manifestations: global developmental delay, progressive neurologic involvement, seizures, and vascular damage. Findings usually appear in the first years of life, in some instances during metabolic stress such as infection or fever. Affected infants typically have severe neck, trunk, and limb hypotonia and loss of head control, sometimes associated with frequent vomiting and loss of social interaction. In addition, chronic diarrhea and failure to thrive are common.</p>
          <p>Atypical findings have also been reported [<xref ref-type="bibr" rid="ee.REF.grosso.2002.1446">Grosso et al 2002</xref>, <xref ref-type="bibr" rid="ee.REF.di_rocco.2006.395">Di Rocco et al 2006</xref>, <xref ref-type="bibr" rid="ee.REF.heberle.2006.329">Heberle et al 2006</xref>, <xref ref-type="bibr" rid="ee.REF.pigeon.2009.991">Pigeon et al 2009</xref>].</p>
          <p><bold>Global developmental delay,</bold> evident in early infancy, manifests later as intellectual disability that ranges from mild to severe. Speech difficulties are common; in some instances speech is absent.</p>
          <p><bold>Progressive neurologic involvement.</bold> Hypotonia evolves into spastic quadriparesis and eventually global neurologic impairment including pyramidal signs such as hypertonia and spasticity with increased deep tendon reflexes (in particular in the lower limbs) with paraparesis. Children may be unable to walk without support and in some instances are wheelchair bound. Difficulty in swallowing is common.</p>
          <p>Dystonia, an extrapyramidal finding, generally involves the limbs and trunk.</p>
          <p>Neurologic deterioration accelerates following intercurrent infectious illness, and the majority of patients die in the early years, although some are still alive in the second decade of life.</p>
          <p><bold>Generalized seizures</bold>. Generalized tonic-clonic seizures are characterized by spasms of the neck, trunk, and arms that could evolve into status epilepticus with decreased level of consciousness.</p>
          <p><bold>Microvasculature injury</bold> is common and is characterized by diffuse and spontaneous relapsing petechial purpura, especially in the trunk and associated with &#x0201c;cutis marmorata&#x0201d; of the extremities.</p>
          <p>Distal orthostatic acrocyanosis with edema of the extremities is often visible.</p>
          <p>Hemorrhagic suffusions of mucosal surfaces and chronic hemorrhagic diarrhea are common manifestations.</p>
          <sec id="ee.Individuals_with_Atypical_Findings">
            <title>Individuals with Atypical Findings</title>
            <p>Of two affected individuals reported by <xref ref-type="bibr" rid="ee.REF.grosso.2002.1446">Grosso et al [2002]</xref>, one had chronic very slow neuromotor deterioration, ataxia, and dysarthria, and the other had acute neonatal onset with severe neuromotor retardation, severe generalized hypotonia, and intractable seizures.</p>
            <p>In one individual with a molecularly confirmed diagnosis, the clinical findings suggested a connective tissue disorder (vascular fragility, joint hyperextensibility, and delayed motor development with normal cognitive development); urinary excretion of ethylmalonic acid was not abnormally increased during intercritical phases [<xref ref-type="bibr" rid="ee.REF.di_rocco.2006.395">Di Rocco et al 2006</xref>].</p>
            <p>One individual who had the typical findings of EE also had hydronephrosis, undescended testes, mild tricuspid regurgitation, and mild dilatation of the pulmonary artery [<xref ref-type="bibr" rid="ee.REF.heberle.2006.329">Heberle et al 2006</xref>].</p>
            <p>Monochorial twins had severe axial hypotonia without petechiae, orthostatic acrocyanosis, or chronic diarrhea. Other clinical findings differed markedly: one twin had an episode of coma at age three years followed by spastic quadriparesis and loss of language; the other had pyramidal involvement (mainly limited to the lower extremities) and spoke two languages [<xref ref-type="bibr" rid="ee.REF.pigeon.2009.991">Pigeon et al 2009</xref>].</p>
            <p><bold>MR spectroscopy</bold> showed a lactate peak in one patient [<xref ref-type="bibr" rid="ee.REF.grosso.2004.755">Grosso et al 2004</xref>].</p>
            <p><bold>Neuropathologic findings</bold> in the brain of an infant age nine months showed widespread luminal microthrombi, acute microhemorrhages, and focal perivascular hemosiderin-laden macrophages, the latter being consistent with previous bleeding. These findings were consistent with both acute and chronic ischemic damage and corresponded with abnormal signal intensity lesions observed on repeat MRI [<xref ref-type="bibr" rid="ee.REF.giordano.2012.451">Giordano et al 2012</xref>].</p>
          </sec>
        </sec>
        <sec id="ee.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>No genotype-phenotype correlations are known to be associated with <italic toggle="yes">ETHE1</italic> biallelic pathogenic variants.</p>
        </sec>
        <sec id="ee.Prevalence">
          <title>Prevalence</title>
          <p>The prevalence of ethylmalonic encephalopathy is unknown. More than 80 individuals with features consistent with EE and a molecularly confirmed diagnosis have been reported [<xref ref-type="bibr" rid="ee.REF.tiranti.2004.239">Tiranti et al 2004</xref>, <xref ref-type="bibr" rid="ee.REF.tiranti.2006.340">Tiranti et al 2006</xref>, <xref ref-type="bibr" rid="ee.REF.mineri.2008.473">Mineri et al 2008</xref>].</p>
          <p>To date, families with EE have been from (or could be traced to) different regions of the Mediterranean basin or the Arabian Peninsula; parental consanguinity is common.</p>
        </sec>
      </sec>
      <sec id="ee.Genetically_Related_Allelic_Disorders">
        <title>Genetically Related (Allelic) Disorders</title>
        <p>At present, no phenotypes other than those discussed in this <italic toggle="yes">GeneReview</italic> are known to be associated with biallelic <italic toggle="yes">ETHE1</italic> pathogenic variants.</p>
      </sec>
      <sec id="ee.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Ethylmalonic acid is a dicarboxylic organic acid produced by the carboxylation of butyrate. Ethylmalonic encephalopathy (EE) should be included in the differential diagnosis of other forms of persistent ethylmalonic aciduria, including the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Defects of beta-oxidation of fatty acids with similar clinical findings (e.g., vomiting, diarrhea, difficulty with feeding, and developmental delay) such as <related-object link-type="booklink" source-id="gene" document-id="scad" document-type="chapter">short-chain acyl-CoA dehydrogenase (SCAD) deficiency</related-object> and 3-hydroxyacyl-CoA dehydrogenase (HADH) deficiency (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/231530">231530</ext-link>). Petechiae, purpura, and orthostatic acrocyanosis are specific to EE [<xref ref-type="bibr" rid="ee.REF.burlina.1994.79">Burlina et al 1994</xref>].</p>
          </list-item>
          <list-item>
            <p>Defects of the mitochondrial electron-transfer flavoprotein pathway or glutaric aciduria type II (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/231680">231680</ext-link>)</p>
          </list-item>
          <list-item>
            <p>Some forms of respiratory chain deficiency</p>
          </list-item>
        </list>
        <p>Of note, brain vascular lesions appear to be a specific neuropathologic feature of EE, not seen in other forms of ethylmalonic aciduria or in disorders caused by primary respiratory chain defects such as <related-object link-type="booklink" source-id="gene" document-id="kss" document-type="chapter">Leigh syndrome</related-object> [<xref ref-type="bibr" rid="ee.REF.giordano.2012.451">Giordano et al 2012</xref>, <xref ref-type="bibr" rid="ee.REF.tiranti.2013.a011437">Tiranti &#x00026; Zeviani 2013</xref>].</p>
      </sec>
      <sec id="ee.Management">
        <title>Management</title>
        <sec id="ee.Evaluations_Following_Initial_Diagnos">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease and needs in an individual diagnosed with ethylmalonic encephalopathy (EE), the recommended evaluations following diagnosis (if not performed as part of the evaluation that led to the diagnosis) are as summarized in <xref ref-type="table" rid="ee.T.recommended_evaluations_following_i">Table 2</xref>.</p>
          <table-wrap id="ee.T.recommended_evaluations_following_i" orientation="portrait" position="anchor">
            <label>Table 2. </label>
            <caption>
              <p>Recommended Evaluations Following Initial Diagnosis of Ethylmalonic Encephalopathy (EE)</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_ee.T.recommended_evaluations_following_i_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Affected System</th>
                  <th id="hd_h_ee.T.recommended_evaluations_following_i_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Evaluation</th>
                  <th id="hd_h_ee.T.recommended_evaluations_following_i_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Comment</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_ee.T.recommended_evaluations_following_i_1_1_1_1" rowspan="3" valign="middle" align="left" scope="row" colspan="1">
                    <bold>Neurologic</bold>
                  </td>
                  <td headers="hd_h_ee.T.recommended_evaluations_following_i_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Neurologic evaluation</td>
                  <td headers="hd_h_ee.T.recommended_evaluations_following_i_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Particularly if medications are being used to treat spasticity and/or extrapyramidal movement disorders (e.g., dystonia)</td>
                </tr>
                <tr>
                  <td headers="hd_h_ee.T.recommended_evaluations_following_i_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Brain MRI</td>
                  <td headers="hd_h_ee.T.recommended_evaluations_following_i_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Indicated in any child w/EE w/seizures or spasticity who has not previously had a brain MRI</td>
                </tr>
                <tr>
                  <td headers="hd_h_ee.T.recommended_evaluations_following_i_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">EEG and video EEG</td>
                  <td headers="hd_h_ee.T.recommended_evaluations_following_i_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">If seizures are suspected</td>
                </tr>
                <tr>
                  <td headers="hd_h_ee.T.recommended_evaluations_following_i_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                    <bold>Gastrointestinal</bold>
                  </td>
                  <td headers="hd_h_ee.T.recommended_evaluations_following_i_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Feeding evaluation &#x00026; nutrition assessment</td>
                  <td headers="hd_h_ee.T.recommended_evaluations_following_i_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Referral to appropriate feeding therapist and/or nutritionist as indicated</td>
                </tr>
                <tr>
                  <td headers="hd_h_ee.T.recommended_evaluations_following_i_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Assessment for chronic diarrhea</td>
                  <td headers="hd_h_ee.T.recommended_evaluations_following_i_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Referral to gastroenterologist as needed</td>
                </tr>
                <tr>
                  <td headers="hd_h_ee.T.recommended_evaluations_following_i_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <bold>Musculoskeletal</bold>
                  </td>
                  <td headers="hd_h_ee.T.recommended_evaluations_following_i_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Orthopedic evaluation</td>
                  <td headers="hd_h_ee.T.recommended_evaluations_following_i_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Referral to orthopedist as needed</td>
                </tr>
                <tr>
                  <td headers="hd_h_ee.T.recommended_evaluations_following_i_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <bold>Miscellaneous /<break/>Other</bold>
                  </td>
                  <td headers="hd_h_ee.T.recommended_evaluations_following_i_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Consultation w/clinical geneticist and/or genetic counselor</td>
                  <td headers="hd_h_ee.T.recommended_evaluations_following_i_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1"/>
                </tr>
              </tbody>
            </table>
          </table-wrap>
        </sec>
        <sec id="ee.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p>Multi-specialty care that includes child neurology, pediatrics, clinical genetics, nutrition, gastroenterology, orthopedic, pain management, and physical therapy can help with timely detection and treatment of the multi-organ dysfunction that characterizes ethylmalonic encephalopathy. Treatment is primarily supportive including anti-spastic medications, muscle relaxants, and antiepileptic drugs. Physical therapy early in the disease course can help prevent contractures.</p>
          <table-wrap id="ee.T.treatment_of_manifestations_in_indi" orientation="portrait" position="anchor">
            <label>Table 3. </label>
            <caption>
              <p>Treatment of Manifestations in Individuals with Ethylmalonic Encephalopathy</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_ee.T.treatment_of_manifestations_in_indi_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Manifestation</th>
                  <th id="hd_h_ee.T.treatment_of_manifestations_in_indi_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Treatment</th>
                  <th id="hd_h_ee.T.treatment_of_manifestations_in_indi_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Considerations/Other</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_ee.T.treatment_of_manifestations_in_indi_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <bold>Spasticity</bold>
                  </td>
                  <td headers="hd_h_ee.T.treatment_of_manifestations_in_indi_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Antispastic medications</td>
                  <td headers="hd_h_ee.T.treatment_of_manifestations_in_indi_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td headers="hd_h_ee.T.treatment_of_manifestations_in_indi_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <bold>Dystonia</bold>
                  </td>
                  <td headers="hd_h_ee.T.treatment_of_manifestations_in_indi_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Muscle relaxants</td>
                  <td headers="hd_h_ee.T.treatment_of_manifestations_in_indi_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td headers="hd_h_ee.T.treatment_of_manifestations_in_indi_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <bold>Contractures</bold>
                  </td>
                  <td headers="hd_h_ee.T.treatment_of_manifestations_in_indi_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Physical therapy</td>
                  <td headers="hd_h_ee.T.treatment_of_manifestations_in_indi_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td headers="hd_h_ee.T.treatment_of_manifestations_in_indi_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <bold>Seizures</bold>
                  </td>
                  <td headers="hd_h_ee.T.treatment_of_manifestations_in_indi_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Antiepileptic drugs</td>
                  <td headers="hd_h_ee.T.treatment_of_manifestations_in_indi_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td headers="hd_h_ee.T.treatment_of_manifestations_in_indi_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <bold>Severe diarrhea</bold>
                  </td>
                  <td headers="hd_h_ee.T.treatment_of_manifestations_in_indi_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Maintain hydration &#x00026; caloric intake</td>
                  <td headers="hd_h_ee.T.treatment_of_manifestations_in_indi_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Tube feeding often necessary</td>
                </tr>
                <tr>
                  <td headers="hd_h_ee.T.treatment_of_manifestations_in_indi_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <bold>Poor energy metabolism &#x00026; oxidative stress</bold>
                  </td>
                  <td headers="hd_h_ee.T.treatment_of_manifestations_in_indi_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">L-carnitine, riboflavin and/or coenzyme Q<sub>10</sub> supplements (a cocktail of drugs generally used in mitochondrial disorders) as well as other vitamin therapies&#x000a0;<sup>1</sup></td>
                  <td headers="hd_h_ee.T.treatment_of_manifestations_in_indi_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1"/>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="ee.TF.3.1">
                <label>1. </label>
                <p>
                  <xref ref-type="bibr" rid="ee.REF.gorman.2016.16080">Gorman et al [2016]</xref>
                </p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p>Off-label compassionate use of N-acetylcysteine (NAC) in combination with metronidazole may be considered as they are the only drugs known to slow disease progression and improve the metabolic abnormalities of EE [<xref ref-type="bibr" rid="ee.REF.viscomi.2010.869">Viscomi et al 2010</xref>, <xref ref-type="bibr" rid="ee.REF.k_l__.2017.293">K&#x00131;l&#x00131;&#x000e7; et al 2017</xref>].</p>
          <list list-type="bullet">
            <list-item>
              <p>N-acetylcysteine (NAC), a cell-permeable precursor of glutathione, is abundant in mitochondria where it can act as one of the physiologic acceptors of the sulfur atom of hydrogen sulfide (H<sub>2</sub>S), which has deficient clearance in persons with EE.</p>
            </list-item>
            <list-item>
              <p>Metronidazole is widely used to combat infections caused by anaerobic bacteria, and can reduce the sulfide-producing bacterial load in the large intestine.</p>
            </list-item>
          </list>
          <sec id="ee.Global_Developmental_Disability__Inte">
            <title>Global Developmental Disability / Intellectual Disability Educational Issues</title>
            <p>The following information represents typical management recommendations for individuals with developmental delay / intellectual disability in the United States; standard recommendations may vary from country to country.</p>
            <p><bold>Ages 0-3 years.</bold> Referral to an early intervention program is recommended for access to occupational, physical, speech, and feeding therapy. In the United States, early intervention is a federally funded program available in all states.</p>
            <p><bold>Ages 3-5 years.</bold> In the United States, developmental preschool through the local public school district is recommended. Before placement, an evaluation is made to determine needed services and therapies, and an individualized education plan (IEP) is developed.</p>
            <p>
              <bold>Ages 5-21 years</bold>
            </p>
            <list list-type="bullet">
              <list-item>
                <p>In the United States, an IEP based on the individual&#x02019;s level of function should be developed by the local public school district. Affected children are permitted to remain in the public school district until age 21.</p>
              </list-item>
              <list-item>
                <p>Discussion about transition plans including financial, vocation/employment, and medical arrangements should begin at age 12 years. Developmental pediatricians can provide assistance with transition to adulthood.</p>
              </list-item>
            </list>
            <p><bold>All ages.</bold> Consultation with a developmental pediatrician is recommended to ensure the involvement of appropriate community, state, and educational agencies and to support parents in maximizing quality of life. Some issues to consider:</p>
            <list list-type="bullet">
              <list-item>
                <p>Private supportive therapies based on the affected individual&#x02019;s needs. Specific recommendations regarding type of therapy can be made by a developmental pediatrician.</p>
              </list-item>
              <list-item>
                <p>In the United States:</p>
                <list list-type="bullet">
                  <list-item>
                    <p>Enrollment in Developmental Disabilities Administration (DDA) is recommended. DDA is a public agency that provides services and supports to qualified individuals. Eligibility differs by state but is typically determined by diagnosis and/or associated cognitive/adaptive disabilities.</p>
                  </list-item>
                  <list-item>
                    <p>Families with limited income and resources may also qualify for supplemental security income (SSI) for their child with a disability.</p>
                  </list-item>
                </list>
              </list-item>
            </list>
          </sec>
          <sec id="ee.Motor_Dysfunction">
            <title>Motor Dysfunction</title>
            <p>
              <bold>Gross motor dysfunction</bold>
            </p>
            <list list-type="bullet">
              <list-item>
                <p>Physical therapy is recommended to maximize mobility and to reduce the risk for later-onset orthopedic complications (e.g., contractures).</p>
              </list-item>
              <list-item>
                <p>Consider use of durable medical equipment as needed (e.g., wheelchairs, walkers, bath chairs, orthotics, adaptive strollers).</p>
              </list-item>
              <list-item>
                <p>For muscle tone abnormalities including hypertonia or dystonia, consider involving appropriate specialists to aid in management of baclofen, Botox<sup>&#x000ae;</sup>, anti-parkinsonian medications, or orthopedic procedures.</p>
              </list-item>
            </list>
            <p><bold>Fine motor dysfunction.</bold> Occupational therapy is recommended for difficulty with fine motor skills that affect adaptive function (e.g., feeding, grooming, dressing, writing).</p>
            <p><bold>Oral motor dysfunction.</bold> Assuming that the individual is safe to eat by mouth, feeding therapy (typically from an occupational or speech therapist) is recommended for affected individuals who have difficulty feeding due to poor oral motor control.</p>
            <p><bold>Communication issues.</bold> Consider evaluation for alternative means of communication (e.g., <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.asha.org/NJC/AAC/">Augmentative and Alternative Communication</ext-link>) for individuals who have expressive language difficulties.</p>
          </sec>
        </sec>
        <sec id="ee.Prevention_of_Secondary_Complications">
          <title>Prevention of Secondary Complications</title>
          <p>All affected individuals should receive routine immunizations; as well as annual immunizations for influenza.</p>
          <p>Physicians must pay particular attention to the prevention of infections that could be fatal.</p>
        </sec>
        <sec id="ee.Surveillance">
          <title>Surveillance</title>
          <p>Surveillance should be individualized based on symptoms and organs affected.</p>
          <table-wrap id="ee.T.recommended_surveillance_for_indivi" orientation="portrait" position="anchor">
            <label>Table 4. </label>
            <caption>
              <p>Recommended Surveillance for Individuals with Ethylmalonic Encephalopathy</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_ee.T.recommended_surveillance_for_indivi_1_1_1_1" valign="top" align="left" scope="col" rowspan="1" colspan="1">System</th>
                  <th id="hd_h_ee.T.recommended_surveillance_for_indivi_1_1_1_2" valign="top" align="left" scope="col" rowspan="1" colspan="1">Evaluation/Action</th>
                  <th id="hd_h_ee.T.recommended_surveillance_for_indivi_1_1_1_3" valign="top" align="left" scope="col" rowspan="1" colspan="1">Frequency</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_ee.T.recommended_surveillance_for_indivi_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <bold>Growth</bold>
                  </td>
                  <td headers="hd_h_ee.T.recommended_surveillance_for_indivi_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Assess growth and monitor for failure to thrive</td>
                  <td headers="hd_h_ee.T.recommended_surveillance_for_indivi_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">At each visit</td>
                </tr>
                <tr>
                  <td headers="hd_h_ee.T.recommended_surveillance_for_indivi_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <bold>Gastrointestinal</bold>
                  </td>
                  <td headers="hd_h_ee.T.recommended_surveillance_for_indivi_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Monitor feeding and electrolyte status, particularly in those with severe diarrhea</td>
                  <td headers="hd_h_ee.T.recommended_surveillance_for_indivi_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td headers="hd_h_ee.T.recommended_surveillance_for_indivi_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <bold>Neurologic</bold>
                  </td>
                  <td headers="hd_h_ee.T.recommended_surveillance_for_indivi_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Monitor for epileptic crisis; modify therapy according to clinical presentation and EEG findings</td>
                  <td headers="hd_h_ee.T.recommended_surveillance_for_indivi_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Routine</td>
                </tr>
              </tbody>
            </table>
          </table-wrap>
        </sec>
        <sec id="ee.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>See <xref ref-type="sec" rid="ee.Related_Genetic_Counseling_Issues">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="ee.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>While clearance of circulating sulfide by a transplanted liver could be beneficial, to date only one instance of liver transplantation in EE has been reported [<xref ref-type="bibr" rid="ee.REF.dionisivici.2016.1045">Dionisi-Vici et al 2016</xref>]. Although results were encouraging, follow up of this patient and experience with additional patients are necessary to determine therapeutic efficacy of liver transplantation in EE and possible relevance for national or state-mandated newborn screening, particularly in populations with relatively high prevalence of pathogenic variants.</p>
          <p>Possible future treatments include AAV-mediated gene therapy [<xref ref-type="bibr" rid="ee.REF.di_meo.2012.1008">Di Meo et al 2012</xref>] or liver transplantation [<xref ref-type="bibr" rid="ee.REF.dionisivici.2016.1045">Dionisi-Vici et al 2016</xref>].</p>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions.</p>
        </sec>
      </sec>
      <sec id="ee.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="ee.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>Ethylmalonic encephalopathy is inherited in an autosomal recessive manner.</p>
        </sec>
        <sec id="ee.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The parents of an affected child are obligate heterozygotes (i.e., carriers of one <italic toggle="yes">ETHE1</italic> pathogenic variant).</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier.</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> No individuals diagnosed with ethylmalonic encephalopathy have been known to reproduce.</p>
          <p><bold>Other family members.</bold> Each sib of the proband&#x02019;s parents is at a 50% risk of being a carrier of an <italic toggle="yes">ETHE1</italic> pathogenic variant.</p>
        </sec>
        <sec id="ee.Carrier_Heterozygote_Detection">
          <title>Carrier (Heterozygote) Detection</title>
          <p>Carrier testing for at-risk relatives requires prior identification of the <italic toggle="yes">ETHE1</italic> pathogenic variants in the family.</p>
        </sec>
        <sec id="ee.Related_Genetic_Counseling_Issues">
          <title>Related Genetic Counseling Issues</title>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected, are carriers, or are at risk of being carriers.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="ee.Prenatal_Testing_and_Preimplantation">
          <title>Prenatal Testing and Preimplantation Genetic Diagnosis</title>
          <p>Once the <italic toggle="yes">ETHE1</italic> pathogenic variants have been identified in an affected family member, prenatal testing for a pregnancy at increased risk and preimplantation genetic diagnosis are possible.</p>
          <p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. Although most centers would consider decisions regarding prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p>
        </sec>
      </sec>
      <sec id="ee.Resources">
        <title>Resources</title>
      </sec>
      <sec id="ee.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <p><bold>Gene structure.</bold>
<italic toggle="yes">ETHE1</italic> comprises seven exons.</p>
        <p><bold>Pathogenic variants.</bold> To date several nonsense and missense pathogenic variants as well as single- and multiexon deletions have been described throughout the gene [<xref ref-type="bibr" rid="ee.REF.tiranti.2006.340">Tiranti et al 2006</xref>, <xref ref-type="bibr" rid="ee.REF.mineri.2008.473">Mineri et al 2008</xref>, <xref ref-type="bibr" rid="ee.REF.tiranti.2013.a011437">Tiranti &#x00026; Zeviani 2013</xref>].</p>
        <p>Deletion of exon 4 and deletion of the entire gene are the most frequent large deletions [<xref ref-type="bibr" rid="ee.REF.mineri.2008.473">Mineri et al 2008</xref>, <xref ref-type="bibr" rid="ee.REF.drousiotou.2011.385">Drousiotou et al 2011</xref>].</p>
        <table-wrap id="ee.T.select_ethe1_pathogenic_variants" orientation="portrait" position="anchor">
          <label>Table 5. </label>
          <caption>
            <p>Select <italic toggle="yes">ETHE1</italic> Pathogenic Variants</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_ee.T.select_ethe1_pathogenic_variants_1_1_1_1" valign="top" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change<break/>(Alias)</th>
                <th id="hd_h_ee.T.select_ethe1_pathogenic_variants_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Predicted Protein Change</th>
                <th id="hd_h_ee.T.select_ethe1_pathogenic_variants_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_ee.T.select_ethe1_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.-83_-79delCGCCC&#x000a0;<sup>1</sup></td>
                <td headers="hd_h_ee.T.select_ethe1_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">--</td>
                <td headers="hd_h_ee.T.select_ethe1_pathogenic_variants_1_1_1_3" rowspan="24" valign="middle" align="left" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/nuccore/NM_014297.3">NM_014297.3</ext-link>
                  <break/>
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/protein/NP_055112.2">NP_055112.2</ext-link>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_ee.T.select_ethe1_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.3G&#x0003e;T</td>
                <td headers="hd_h_ee.T.select_ethe1_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Met1Ile</td>
              </tr>
              <tr>
                <td headers="hd_h_ee.T.select_ethe1_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.34C&#x0003e;T</td>
                <td headers="hd_h_ee.T.select_ethe1_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Gln12Ter</td>
              </tr>
              <tr>
                <td headers="hd_h_ee.T.select_ethe1_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.66delC</td>
                <td headers="hd_h_ee.T.select_ethe1_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Ile23SerfsTer10</td>
              </tr>
              <tr>
                <td headers="hd_h_ee.T.select_ethe1_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.113A&#x0003e;G</td>
                <td headers="hd_h_ee.T.select_ethe1_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Tyr38Cys</td>
              </tr>
              <tr>
                <td headers="hd_h_ee.T.select_ethe1_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.131_132delAG</td>
                <td headers="hd_h_ee.T.select_ethe1_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Glu44ValfsTer62</td>
              </tr>
              <tr>
                <td headers="hd_h_ee.T.select_ethe1_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.164T&#x0003e;C</td>
                <td headers="hd_h_ee.T.select_ethe1_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Leu55Pro</td>
              </tr>
              <tr>
                <td headers="hd_h_ee.T.select_ethe1_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.187C&#x0003e;T</td>
                <td headers="hd_h_ee.T.select_ethe1_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Gln63Ter</td>
              </tr>
              <tr>
                <td headers="hd_h_ee.T.select_ethe1_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.222_223insA</td>
                <td headers="hd_h_ee.T.select_ethe1_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Ala75SerfsTer32</td>
              </tr>
              <tr>
                <td headers="hd_h_ee.T.select_ethe1_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.230delA</td>
                <td headers="hd_h_ee.T.select_ethe1_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Asn77IlefsTer68</td>
              </tr>
              <tr>
                <td headers="hd_h_ee.T.select_ethe1_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.375+5G&#x0003e;A</td>
                <td headers="hd_h_ee.T.select_ethe1_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">--</td>
              </tr>
              <tr>
                <td headers="hd_h_ee.T.select_ethe1_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.406A&#x0003e;G</td>
                <td headers="hd_h_ee.T.select_ethe1_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Thr136Ala</td>
              </tr>
              <tr>
                <td headers="hd_h_ee.T.select_ethe1_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.440_450del11</td>
                <td headers="hd_h_ee.T.select_ethe1_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.His147LeufsTer30</td>
              </tr>
              <tr>
                <td headers="hd_h_ee.T.select_ethe1_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.455C&#x0003e;T</td>
                <td headers="hd_h_ee.T.select_ethe1_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Thr152Ile</td>
              </tr>
              <tr>
                <td headers="hd_h_ee.T.select_ethe1_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.482G&#x0003e;A</td>
                <td headers="hd_h_ee.T.select_ethe1_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Cys161Tyr</td>
              </tr>
              <tr>
                <td headers="hd_h_ee.T.select_ethe1_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.487C&#x0003e;G</td>
                <td headers="hd_h_ee.T.select_ethe1_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg163Gly</td>
              </tr>
              <tr>
                <td headers="hd_h_ee.T.select_ethe1_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.487C&#x0003e;T</td>
                <td headers="hd_h_ee.T.select_ethe1_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg163Trp</td>
              </tr>
              <tr>
                <td headers="hd_h_ee.T.select_ethe1_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.488G&#x0003e;A</td>
                <td headers="hd_h_ee.T.select_ethe1_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg163Gln</td>
              </tr>
              <tr>
                <td headers="hd_h_ee.T.select_ethe1_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.491C&#x0003e;A</td>
                <td headers="hd_h_ee.T.select_ethe1_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Thr164Lys</td>
              </tr>
              <tr>
                <td headers="hd_h_ee.T.select_ethe1_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.505+1G&#x0003e;T</td>
                <td headers="hd_h_ee.T.select_ethe1_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">--</td>
              </tr>
              <tr>
                <td headers="hd_h_ee.T.select_ethe1_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.554T&#x0003e;G</td>
                <td headers="hd_h_ee.T.select_ethe1_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Leu185Arg</td>
              </tr>
              <tr>
                <td headers="hd_h_ee.T.select_ethe1_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.586G&#x0003e;A</td>
                <td headers="hd_h_ee.T.select_ethe1_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Asp196Asn</td>
              </tr>
              <tr>
                <td headers="hd_h_ee.T.select_ethe1_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.592dupC<break/>(592_593insC)&#x000a0;<sup>2</sup></td>
                <td headers="hd_h_ee.T.select_ethe1_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.His198fsProTer23</td>
              </tr>
              <tr>
                <td headers="hd_h_ee.T.select_ethe1_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.604dupG<break/>(604_605insG)&#x000a0;<sup>2</sup></td>
                <td headers="hd_h_ee.T.select_ethe1_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Val202GlyfsTer19</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
            </fn>
            <fn>
              <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
            </fn>
            <fn id="ee.TF.5.1">
              <label>1. </label>
              <p>HGVS nomenclature: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/nuccore/NG_008141.1">NG_008141.1</ext-link>:g.4985_4989delCGCCC, as c.-83_79delCGCCC is not encompassed in the RefSeq <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/nuccore/NM_014297.3">NM_014297.3</ext-link>.</p>
            </fn>
            <fn id="ee.TF.5.2">
              <label>2. </label>
              <p>Originally reported with designation that does not conform to current naming conventions</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p><bold>Normal gene product.</bold> ETHE1, a 30-kd polypeptide exclusively located in the mitochondrial matrix, is a homodimeric Fe-containing sulfur dioxygenase (SDO). It has a beta-lactamase domain that is involved in the catabolic oxidation of hydrogen sulfide (H<sub>2</sub>S) to sulfate [<xref ref-type="bibr" rid="ee.REF.di_meo.2015.1257">Di Meo et al 2015</xref>].</p>
        <p><bold>Abnormal gene product.</bold> Impaired activity of ETHE1-SDO in ethylmalonic encephalopathy leads to the accumulation of H<sub>2</sub>S in critical tissues (including colonic mucosa, liver, muscle, and brain) up to concentrations that inhibit short-chain acyl-CoA dehydrogenase (SCAD) and cytochrome c oxidase (COX) activities, thus inducing high plasma levels of C4- and C5-acylcarnitines, ethylmalonic acid, and lactate [<xref ref-type="bibr" rid="ee.REF.di_meo.2015.1257">Di Meo et al 2015</xref>].</p>
      </sec>
      <sec id="ee.References">
        <title>References</title>
        <sec id="ee.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="ee.Literature_Cited.reflist0">
            <ref id="ee.REF.burlina.1994.79">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Burlina</surname>
                    <given-names>AB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dionisi-Vici</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bennett</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gibson</surname>
                    <given-names>KM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Servidei</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bertini</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hale</surname>
                    <given-names>DE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schmidt-Sommerfeld</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sabetta</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zacchello</surname>
                    <given-names>F</given-names>
                  </name>
                  <etal/>
                </person-group>
                <article-title>A new syndrome with ethylmalonic aciduria and normal fatty acid oxidation in fibroblasts.</article-title>
                <source>J Pediatr.</source>
                <year>1994</year>
                <volume>124</volume>
                <fpage>79</fpage>
                <lpage>86</lpage>
                <pub-id pub-id-type="pmid">8283379</pub-id>
              </element-citation>
            </ref>
            <ref id="ee.REF.di_meo.2012.1008">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Di Meo</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Auricchio</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lamperti</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burlina</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Viscomi</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zeviani</surname>
                    <given-names>M.</given-names>
                  </name>
                </person-group>
                <article-title>Effective AAV-mediated gene therapy in a mouse model of ethylmalonic encephalopathy.</article-title>
                <source>EMBO Mol Med</source>
                <year>2012</year>
                <volume>4</volume>
                <fpage>1008</fpage>
                <lpage>14</lpage>
                <pub-id pub-id-type="pmid">22903887</pub-id>
              </element-citation>
            </ref>
            <ref id="ee.REF.di_meo.2015.1257">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Di Meo</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lamperti</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tiranti</surname>
                    <given-names>V</given-names>
                  </name>
                </person-group>
                <article-title>Mitochondrial diseases caused by toxic compound accumulation: from etiopathology to therapeutic approaches.</article-title>
                <source>EMBO Mol Med</source>
                <year>2015</year>
                <volume>7</volume>
                <fpage>1257</fpage>
                <lpage>66</lpage>
                <pub-id pub-id-type="pmid">26194912</pub-id>
              </element-citation>
            </ref>
            <ref id="ee.REF.dionisivici.2016.1045">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Dionisi-Vici</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Diodato</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Torre</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Picca</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pariante</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giuseppe Picardo</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Di Meo</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rizzo</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tiranti</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zeviani</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>De GoyetJde V. Liver transplant in ethylmalonic encephalopathy: a new treatment for an otherwise fatal disease.</article-title>
                <source>Brain</source>
                <year>2016</year>
                <volume>139</volume>
                <fpage>1045</fpage>
                <lpage>51</lpage>
                <pub-id pub-id-type="pmid">26917598</pub-id>
              </element-citation>
            </ref>
            <ref id="ee.REF.di_rocco.2006.395">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Di Rocco</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Caruso</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Briem</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rossi</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Allegri</surname>
                    <given-names>AE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Buzzi</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tiranti</surname>
                    <given-names>V</given-names>
                  </name>
                </person-group>
                <article-title>A case of ethylmalonic encephalopathy with atypical clinical and biochemical presentation.</article-title>
                <source>Mol Genet Metab.</source>
                <year>2006</year>
                <volume>89</volume>
                <fpage>395</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">16828325</pub-id>
              </element-citation>
            </ref>
            <ref id="ee.REF.drousiotou.2011.385">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Drousiotou</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>DiMeo</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mineri</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Georgiou</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stylianidou</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tiranti</surname>
                    <given-names>V.</given-names>
                  </name>
                </person-group>
                <article-title>Ethylmalonic encephalopathy: application of improved biochemical and molecular diagnostic approaches.</article-title>
                <source>Clin Genet</source>
                <year>2011</year>
                <volume>79</volume>
                <fpage>385</fpage>
                <lpage>90</lpage>
                <pub-id pub-id-type="pmid">20528888</pub-id>
              </element-citation>
            </ref>
            <ref id="ee.REF.giordano.2012.451">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Giordano</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Viscomi</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Orlandi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Papoff</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Spalice</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burlina</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Di Meo</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tiranti</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leuzzi</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>d&#x02019;Amati</surname>
                    <given-names>G</given-names>
                  </name>
                  <etal/>
                </person-group>
                <article-title>Morphologic evidence of diffuse vascular damage in human and in the experimental model of ethylmalonic encephalopathy.</article-title>
                <source>J Inherit Metab Dis</source>
                <year>2012</year>
                <volume>35</volume>
                <fpage>451</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">22020834</pub-id>
              </element-citation>
            </ref>
            <ref id="ee.REF.gorman.2016.16080">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gorman</surname>
                    <given-names>GS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chinnery</surname>
                    <given-names>PF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>DiMauro</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hirano</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koga</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McFarland</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suomalainen</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thorburn</surname>
                    <given-names>DR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zeviani</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Turnbull</surname>
                    <given-names>DM</given-names>
                  </name>
                </person-group>
                <article-title>Mitochondrial diseases.</article-title>
                <source>Nat Rev Dis Primers.</source>
                <year>2016</year>
                <volume>2</volume>
                <fpage>16080</fpage>
                <pub-id pub-id-type="pmid">27775730</pub-id>
              </element-citation>
            </ref>
            <ref id="ee.REF.grosso.2002.1446">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Grosso</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mostardini</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Farnetani</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Molinelli</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berardi</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dionisi-Vici</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rizzo</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morgese</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Balestri</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <article-title>Ethylmalonic encephalopathy: further clinical and neuroradiological characterization.</article-title>
                <source>J Neurol.</source>
                <year>2002</year>
                <volume>249</volume>
                <fpage>1446</fpage>
                <lpage>50</lpage>
                <pub-id pub-id-type="pmid">12382164</pub-id>
              </element-citation>
            </ref>
            <ref id="ee.REF.grosso.2004.755">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Grosso</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Balestri</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mostardini</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Federico</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Stefano</surname>
                    <given-names>N</given-names>
                  </name>
                </person-group>
                <article-title>Brain mitochondrial impairment in ethylmalonic encephalopathy.</article-title>
                <source>J Neurol.</source>
                <year>2004</year>
                <volume>251</volume>
                <fpage>755</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">15311356</pub-id>
              </element-citation>
            </ref>
            <ref id="ee.REF.heberle.2006.329">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Heberle</surname>
                    <given-names>LC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Al Tawari</surname>
                    <given-names>AA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ramadan</surname>
                    <given-names>DG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ibrahim</surname>
                    <given-names>JK</given-names>
                  </name>
                </person-group>
                <article-title>Ethylmalonic encephalopathy: report of two cases.</article-title>
                <source>Brain Dev.</source>
                <year>2006</year>
                <volume>28</volume>
                <fpage>329</fpage>
                <lpage>31</lpage>
                <pub-id pub-id-type="pmid">16376514</pub-id>
              </element-citation>
            </ref>
            <ref id="ee.REF.k_l__.2017.293">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>K&#x00131;l&#x00131;&#x000e7;</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dedeo&#x0011f;lu</surname>
                    <given-names>&#x000d6;</given-names>
                  </name>
                  <name name-style="western">
                    <surname>G&#x000f6;&#x000e7;men</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kesici</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Y&#x000fc;ksel</surname>
                    <given-names>D.</given-names>
                  </name>
                </person-group>
                <article-title>Successful treatment of a patient with ethylmalonic encephalopathy by intravenous N-acetylcysteine.</article-title>
                <source>Metabolic Brain Disease</source>
                <year>2017</year>
                <volume>32</volume>
                <fpage>293</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">27830356</pub-id>
              </element-citation>
            </ref>
            <ref id="ee.REF.mchugh.2011.230">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>McHugh</surname>
                    <given-names>D</given-names>
                  </name>
                  <etal/>
                </person-group>
                <article-title>Clinical validation of cutoff target ranges in newborn screening of metabolic disorders by tandem mass spectrometry: a worldwide collaborative project.</article-title>
                <source>Genet Med.</source>
                <year>2011</year>
                <volume>13</volume>
                <fpage>230</fpage>
                <lpage>54</lpage>
                <pub-id pub-id-type="pmid">21325949</pub-id>
              </element-citation>
            </ref>
            <ref id="ee.REF.merinero.2006.685">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Merinero</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>P&#x000e9;rez-Cerd&#x000e1;</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ruiz Sala</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferrer</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garc&#x000ed;a</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mart&#x000ed;nez Pardo</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Belanger-Quintana</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de la Mota</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martin-Hern&#x000e1;ndez</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vianey-Saban</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bischoff</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gregersen</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ugarte</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>Persistent increase of plasma butyryl/isobutyrylcarnitine concentrations as marker of SCAD defect and ethylmalonic encephalopathy.</article-title>
                <source>J Inherit Metab Dis.</source>
                <year>2006</year>
                <volume>29</volume>
                <fpage>685</fpage>
                <pub-id pub-id-type="pmid">16906473</pub-id>
              </element-citation>
            </ref>
            <ref id="ee.REF.mineri.2008.473">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mineri</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rimoldi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burlina</surname>
                    <given-names>AB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koskull</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Perletti</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heese</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>von D&#x000f6;beln</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mereghetti</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Di Meo</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Invernizzi</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zeviani</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Uziel</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tiranti</surname>
                    <given-names>V</given-names>
                  </name>
                </person-group>
                <article-title>Identification of new mutations in the ETHE1 gene in a cohort of 14 patients presenting with ethylmalonic encephalopathy.</article-title>
                <source>J Med Genet.</source>
                <year>2008</year>
                <volume>45</volume>
                <fpage>473</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">18593870</pub-id>
              </element-citation>
            </ref>
            <ref id="ee.REF.pigeon.2009.991">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pigeon</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Campeau</surname>
                    <given-names>PM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cyr</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lemieux</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clarke</surname>
                    <given-names>JT</given-names>
                  </name>
                </person-group>
                <article-title>Clinical heterogeneity in ethylmalonic encephalopathy.</article-title>
                <source>J Child Neurol.</source>
                <year>2009</year>
                <volume>24</volume>
                <fpage>991</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">19289697</pub-id>
              </element-citation>
            </ref>
            <ref id="ee.REF.tiranti.2006.340">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tiranti</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Briem</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lamantea</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mineri</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Papaleo</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Gioia</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Forlani</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rinaldo</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dickson</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abu-Libdeh</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cindro-Heberle</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Owaidha</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jack</surname>
                    <given-names>RM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Christensen</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burlina</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zeviani</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>ETHE1 mutations are specific to ethylmalonic encephalopathy.</article-title>
                <source>J Med Genet.</source>
                <year>2006</year>
                <volume>43</volume>
                <fpage>340</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">16183799</pub-id>
              </element-citation>
            </ref>
            <ref id="ee.REF.tiranti.2004.239">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tiranti</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>D'Adamo</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Briem</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferrari</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mineri</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lamantea</surname>
                    <given-names>E</given-names>
                  </name>
                  <etal/>
                </person-group>
                <article-title>Ethylmalonic encephalopathy is caused by mutations in ETHE1, a gene encoding a mitochondrial matrix protein.</article-title>
                <source>Am J Hum Genet</source>
                <year>2004</year>
                <volume>74</volume>
                <fpage>239</fpage>
                <lpage>52</lpage>
                <pub-id pub-id-type="pmid">14732903</pub-id>
              </element-citation>
            </ref>
            <ref id="ee.REF.tiranti.2013.a011437">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tiranti</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zeviani</surname>
                    <given-names>M.</given-names>
                  </name>
                </person-group>
                <article-title>Altered sulfide (H(2)S) metabolism in ethylmalonic encephalopathy.</article-title>
                <source>Cold Spring Harb Perspect Biol</source>
                <year>2013</year>
                <volume>5</volume>
                <fpage>a011437</fpage>
                <pub-id pub-id-type="pmid">23284046</pub-id>
              </element-citation>
            </ref>
            <ref id="ee.REF.viscomi.2010.869">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Viscomi</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burlina</surname>
                    <given-names>AB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dweikat</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Savoiardo</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lamperti</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hildebrandt</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tiranti</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zeviani</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>Combined treatment with oral metronidazole and N-ace-tylcysteine is effective in ethylmalonic encephalopathy.</article-title>
                <source>Nat Med</source>
                <year>2010</year>
                <volume>16</volume>
                <fpage>869</fpage>
                <lpage>71</lpage>
                <pub-id pub-id-type="pmid">20657580</pub-id>
              </element-citation>
            </ref>
            <ref id="ee.REF.zafeiriou.2007.78">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zafeiriou</surname>
                    <given-names>DI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Augoustides-Savvopoulou</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haas</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smet</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Triantafyllou</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vargiami</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tamiolaki</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gombakis</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Coster</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sewell</surname>
                    <given-names>AC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vianey-Saban</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gregersen</surname>
                    <given-names>N</given-names>
                  </name>
                </person-group>
                <article-title>Ethylmalonic encephalopathy: clinical and biochemical observations.</article-title>
                <source>Neuropediatrics.</source>
                <year>2007</year>
                <volume>38</volume>
                <fpage>78</fpage>
                <lpage>82</lpage>
                <pub-id pub-id-type="pmid">17712735</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="ee.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="ee.Acknowledgments">
          <title>Acknowledgments</title>
          <p>AD is supported by the Max Kade foundation and the gift from Carl Edward Bolch, Jr, and Susan Bass Bolch. This work is also supported by NINDS R01 NS078086 (OAR). ZKW is partially supported by the NIH/NINDS P50 NS072187, NIH/NIA (primary) and NIH/NINDS (secondary) 1U01AG045390-01A1, Mayo Clinic Center for Regenerative Medicine, Mayo Clinic Center for Individualized Medicine, Mayo Clinic Neuroscience Focused Research Team (Cecilia and Dan Carmichael Family Foundation, and the James C and Sarah K Kennedy Fund for Neurodegenerative Disease Research at Mayo Clinic in Florida), the gift from Carl Edward Bolch, Jr, and Susan Bass Bolch, The Sol Goldman Charitable Trust, and Donald G and Jodi P Heeringa.</p>
        </sec>
        <sec id="ee.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>21 September 2017 (bp) Review posted live</p>
            </list-item>
            <list-item>
              <p>23 August 2016 (vt) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
